Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 6/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.36 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1752248 | 0.89 | GPR119 (0.38) | RENGPR119 | |
| SCHEMBL12750489 | 0.79 | REN (0.36) | RENGPR119CYP3A4 | |
| SCHEMBL1751975 | 0.76 | CYP3A4 (0.42) | RENGPR119CYP3A4NR1H2 | |
| SCHEMBL556513 | 0.75 | KCNH2 (0.47) | RENGPR119CYP3A4 | |
| SCHEMBL3264631 | 0.75 | KCNH2 (0.47) | RENGPR119CYP3A4 | |
| SCHEMBL3264633 | 0.75 | KCNH2 (0.47) | RENGPR119CYP3A4 | |
| SCHEMBL4785830 | 0.75 | REN (0.36) | RENGPR119CYP3A4NR1H2 | |
| SCHEMBL5668307 | 0.75 | REN (0.41) | RENGPR119CYP3A4 | |
| SCHEMBL5668304 | 0.75 | REN (0.41) | RENGPR119CYP3A4 | |
| SCHEMBL1752405 | 0.75 | REN (0.41) | RENGPR119CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968720-B2 | Secondary amines as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-06-28 | — | — | US | disclosed |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-07-09 | — | — | US | disclosed |
| EP-1981847-A1 | SECONDARY AMINES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007088514-A1 | SECONDARY AMINES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | REN, ACE, AGTR1 | REN 1/4885GPR119 353/4885TNK2 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.